AngioDynamics (NASDAQ:ANGO) Releases Earnings Results, Beats Expectations By $0.16 EPS

AngioDynamics (NASDAQ:ANGO - Get Free Report) released its quarterly earnings data on Wednesday. The medical instruments supplier reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.13) by $0.16, Zacks reports. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company had revenue of $72.00 million for the quarter, compared to the consensus estimate of $70.30 million. The firm's revenue was down 4.3% compared to the same quarter last year. AngioDynamics updated its FY 2025 guidance to -0.340--0.310 EPS and its FY25 guidance to ($0.34)-($0.31) EPS.

AngioDynamics Stock Down 0.2 %

Shares of NASDAQ ANGO traded down $0.02 during trading hours on Tuesday, hitting $9.29. 295,495 shares of the stock were exchanged, compared to its average volume of 572,065. The firm has a fifty day moving average price of $10.10 and a 200-day moving average price of $8.90. AngioDynamics has a 12 month low of $5.47 and a 12 month high of $13.50. The company has a market cap of $375.85 million, a PE ratio of -1.65 and a beta of 0.52.

Insider Transactions at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the sale, the senior vice president now directly owns 41,817 shares in the company, valued at $514,767.27. This trade represents a 8.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 5.40% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and set a $16.00 target price (up previously from $15.00) on shares of AngioDynamics in a research report on Monday.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.